Skip to main content

Public Hearings

Annual Drug Price Transparency public hearings

The Department of Consumer and Business Services held its second annual Prescription Drug Price Hearing on Wednesday, Dec. 16. Due to COVID-19, the hearing was held virtually.

The hearing provided time for public comment and covered several topics, including an overview of the Drug Price Transparency Program, results from data collected, and panels on drug pricing issues – including a discussion of pricing for COVID-19 therapeutics.

The recording of the hearing will be available on this page in January. In the meantime, view the presentations, reports, and written testimony that was referenced during the hearing.

Share your Rx drug price story

Watch the 2019 Prescription Drug Price Hearing Here:

Nov. 19 public hearing materials
Presciption Drug Price Transparency Hearing Presentation
Bill Head, Pharmaceutical Care Management Association: OIG Report
Bill Head, Pharmaceutical Care Management Association: GAO Report
Daniel Hartung, Oregon State University and Oregon Health Sciences University: Presentation
Saumil Pandya, Pharmaceutical Research and Manufacturers of America: Presentation
Saumil Pandya, Pharmaceutical Research and Manufacturers of America: Written Testimony
Mihir Patel, PacificSource Health Plans: Written Testimony

For more information about the Drug Price Transparency Program:


Your browser is out-of-date! It has known security flaws and may not display all features of this and other websites. Learn how

×